Kevin Forrest Appointed as Venture Partner at Scion Life Sciences

Scion Life Sciences has appointed Kevin Forrest as Venture Partner, adding a seasoned biotechnology executive and investor to its team. Forrest brings 21 years of experience across investing and company building, most recently as co-founder and Chief Executive Officer of Kate Therapeutics, which they led for four years.

A Track Record In Investing

Forrest began a career in life sciences investing in 2005 as Principal at 5AM Ventures, the same year they completed a PhD in Molecular Biology at Princeton University, following a BS in Biology from Boston College. According to Crustdata people data, the move into operating leadership came at Cidara Therapeutics, where Forrest served as Chief Operating Officer from 2014, Chief Financial Officer from 2015 and Chief Strategy Officer from 2016.

The top job arrived in 2018, when Forrest became Chief Executive Officer of Expansion Therapeutics. In September 2020, Forrest co-founded Kate Therapeutics and guided the company as its chief executive for four years, adding a founder's perspective to a résumé already rich in finance, strategy and operations.

Why It Matters For Scion Life Sciences

Founded in 2020 and headquartered in New York, Scion Life Sciences is a life sciences venture capital firm focused on improving human health through long-term ownership of new therapies. Its team of innovators, company-builders and investors founds and builds biotechnology companies to discover, develop and commercialize curative or clinically transformational new medicines.

Crustdata company data shows the firm employs 15 people across the United States, with its team concentrated in the New York City Metropolitan Area and Greater Boston. For a firm whose model centers on creating companies, a Venture Partner who has worked as a co-founder, chief executive and investor is a natural fit.

What's Next

Forrest took on the Venture Partner role in September 2026 and works from San Diego, extending the firm's presence beyond New York and Greater Boston. The appointment pairs an early grounding in venture investing at 5AM Ventures with years of hands-on leadership at the helm of biotechnology companies, a combination well suited to a firm built around founding and building the next generation of medicines companies.